Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

Similar Items

• Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
  od: Ascierto, Paolo Antonio, i dr.
  Izdano: (2020)
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
  od: Wolchok, J.D., i dr.
  Izdano: (2017)
• Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
  Izdano: (2020)
• A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
  od: Dummer, Reinhard, i dr.
  Izdano: (2015)
• Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
  od: Grimaldi, Antonio M, i dr.
  Izdano: (2014)